NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN.

SHOP APOTHEKE EUROPE N.V. PUBLISHES EGM CONVOCATION AND AGENDA.

Venlo, 25 September 2017. SHOP APOTHEKE EUROPE N.V. ("SHOP APOTHEKE EUROPE" or the "Company"), Continental Europe's leading online OTC pharmacy (OTC = over the counter = non-prescription medications), has today published the convocation for an extraordinary general meeting of shareholders of the Company (the "EGM"), including the agenda, the accompanying explanatory notes, the shareholders circular and other information/documentation on its website
http://shop-apotheke-europe.com/en/investorrelations/hauptversammlung/ausserordentliche_hauptversammlung.html.
 

The EGM will take place on 6 November 2017 at 10:00 CEST at at Innovatoren Building, ground floor, room name "The Box", Sint Jansweg 15, 5928 RC Venlo, The Netherlands.

ABOUT SHOP APOTHEKE EUROPE.

SHOP APOTHEKE EUROPE is Continental Europe's leading online OTC pharmacy with a portfolio that focuses on OTC medication and pharmacy-related beauty and care products (BPC). The Company operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, the TÜV-certified shop-apotheke.com is the market leader in terms of traffic. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to more than 2.2 million active customers quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE generated sales of about EUR 127 million in the first half of 2017 and a growth of +54% compared to the same period last year. Headquartered in Venlo (the Netherlands), SHOP APOTHEKE EUROPE also has offices in Cologne, Düsseldorf, Paris and Tongeren, Belgium. The online pharmacy has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.

CONTACT.

Investor Relations:
Dr. Ulrich Wandel
Phone: +31 77 850 6117
E-Mail: ulrich.wandel@shop-apotheke.com

DISCLAIMER.

This public announcement constitutes neither an offer, nor any part of an offer, nor any solicitation of any offer, to sell or buy or subscribe for any securities in SHOP APOTHEKE EUROPE in any jurisdiction. This is not a securities prospectus. Any public offering will be made solely by means of, and on the basis of, a securities prospectus. An investment decision regarding the securities of SHOP APOTHEKE EUROPE should only be made on the basis of the securities prospectus. Any securities prospectus will be published promptly upon approval by the Autoriteit Financiële Markten (AFM) and posted on http://shop-apotheke-europe.com/de/investorrelations/.

Statements contained herein may constitute "forward-looking statements." Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "plan", "expect", "anticipate", "estimate," "believe", "intend", "project", "goal" or "target" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on current expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause SHOP APOTHEKE EUROPE's (including its subsidiaries and affiliates) or its industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. You should not place undue reliance on forward-looking statements and SHOP APOTHEKE EUROPE (including its subsidiaries and affiliates) does not undertake publicly to update or revise any forward-looking statement that may be made herein, whether as a result of new information, future events or otherwise.